Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ganglionic parasympathetic inhibitor.
Market Analysis and Insights: Global Mepenzolate Market
Due to the COVID-19 pandemic, the global Mepenzolate market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Hospital accounting for % of the Mepenzolate global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Spasmolytic Agent segment is altered to an % CAGR throughout this forecast period.
China Mepenzolate market size is valued at US$ million in 2021, while the US and Europe Mepenzolate are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Mepenzolate landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Mepenzolate include Yu Sheng, Astellas Pharma, Johnson and Johnson, Tsuruhara Seiyaku Pharmaceutical, Century Pharmaceuticals, Peili Pharmaceuticals, Chin Teng Pharmaceutical and Sanofi-Aventis, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Mepenzolate Scope and Segment
Mepenzolate market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Mepenzolate market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Hospital
Drug Store
Segment by Application
Spasmolytic Agent
Muscarinic Receptor Antagonist
By Company
Yu Sheng
Astellas Pharma
Johnson and Johnson
Tsuruhara Seiyaku Pharmaceutical
Century Pharmaceuticals
Peili Pharmaceuticals
Chin Teng Pharmaceutical
Sanofi-Aventis
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE